Marker Therapeutics is dedicated to the development and commercialization of next-generation T cell-based immunotherapies for patients with a wide range of blood and solid tumor cancers.
- Year invested 2018
- Investment Stage Early
- Sectors
- Investment Status Current
- Associated Team
- Website markertherapeutics.com
- Company Status IPO/Public (NASDAQ: MRKR)